date:Feb 24, 2014
is for a GRAS determination and whether information in the notice or otherwise available to FDA raises issues that lead the agency to question whether use of the substance is GRAS.
But CFS claims that FDA no longer conducts its own detailed analysis to evaluate the data and no longer affirms whether or not a substances use is GRAS at all.
A 2010 Government Accountability Office (GAO) report on the subject passed similar judgment by stating, Currently, companies may determine a substance is GRA